These two companies are profiting from the spate of new and confusing government rules governing health care. Read More

This company is poised to gain from the huge projected need for medical-related isotopes. Read More

These two China-based defense contractors are benefiting from the country’s ramped-up military ambitions. Read More

This drug firm could hold the key to ameliorating an intractable neurological disease. Read More

Prompted by Obamacare’s strictures, the dominant carriers in California are exiting the state’s individual health insurance market. Here’s what it all means for the health care industry in the Golden State. Read More

This Spanish biotech faces huge growth prospects for its leading edge treatments that could alleviate a host of intractable diseases. Read More

This innovative drug could finally help Americans prevail against their ever-expanding waistlines. Read More

Although the drugmaker’s treatment for hepatitis C has shown great promise during clinical trials, investors still have time to take advantage of this stock before shares head higher in anticipation of the drug’s approval. Read More

Heart disease is the leading cause of death worldwide, and these three companies have developed innovative treatments that could soon improve outcomes for millions of people. Read More

The healthcare industry is set to undergo massive growth, but ETFs aren’t sufficiently focused to exploit this trend. So we’ve shifted our emphasis from selecting the right ETF to finding the best healthcare stocks. Read More